静脉乌司奴单抗再诱导对既往生物制剂治疗失败且已每4周给药的克罗恩病患者有效
Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-08-04
本研究评估静脉乌司奴单抗再诱导对已每4周皮下维持给药且部分应答或应答丧失的克罗恩病患者的疗效。这些患者既往生物制剂治疗失败,再诱导后评估应答率和缓解率。
要点
- 评估静脉乌司奴单抗再诱导对已每4周给药且部分应答或应答丧失的克罗恩病患者的应答率和缓解率。
- 研究对象为既往生物制剂治疗失败的克罗恩病患者。
- 静脉再诱导的应答率和缓解率是主要观察指标。
核心结论
- 静脉乌司奴单抗再诱导对已每4周皮下维持给药且部分应答或应答丧失的克罗恩病患者可能有效。
研究设计与样本
- 评估静脉乌司奴单抗再诱导对已每4周皮下维持给药且部分应答或应答丧失的克罗恩病患者的应答率和缓解率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ustekinumab (UST) targets the common subunit (p40) of interleukins-12/23,1,2 approved for intravenous (IV) induction of remission in moderate-to-severe Crohn's disease (CD), followed by subcutaneous (SC) doses for maintenance of remission.3,4 The role of IV reinduction of UST in patients already on every-4-week (Q4) maintenance with partial response or loss of response (LOR) is unclear.5 The aim was to assess response and remission rates for UST IV reinduction in patients with CD with partial response or LOR who already were on Q4 SC dosing and had failed prior biological therapies.
来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。
引用
- Sedano R, Guizzetti L, McDonald C, et al. Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing. Clin Gastroenterol Hepatol. 2020. PMID: 32763479. doi:10.1016/j.cgh.2020.07.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。